|
| HOME |
|
Archive News
2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002
To download and view any of the documents listed below, click on the links. To view or print the Portable Document Format (PDF) files, you will need Adobe Acrobat Viewer installed on your system.
If you do not have the latest Adobe Viewer, please download it here before you attempt to open the desired file.
| 2006 |
|
|
| December 21, 2006 |
2007 Notice of Annual General Meeting & Proxy Form |
|
| December 18, 2006 |
Peptech Lists on AIM |
|
| December 11, 2006 |
Peptech to deepen product pipeline following Domantis sale |
|
| December 8, 2006 |
Peptech realises A$178m on Domantis’ GSK deal |
|
| December 4, 2006 |
Peptech acquires new cancer products |
|
| November 20, 2006 |
Director escrow arrangements |
|
| November 20, 2006 |
Peptech AIM Listing |
|
| November 20, 2006 |
The Peptech Investment Circular |
|
| November 20, 2006 |
Peptech AIM Pre-Admission announcement |
|
| November 2, 2006 |
EvoGenix announced that it had been selected by the US National Institutes of Health to collaborate in a program to develop antibody therapeutics directed against a novel cancer target |
|
| November 3, 2006 |
2006 Full Year Results |
|
| November 3, 2006 |
Peptech continues to deliver on growth strategy |
|
| October 24, 2006 |
EvoGenix announced that it had reported to GlaxoSmithKline on completion of the first project under the technology collaboration between the two companies. |
|
| October 16, 2006 |
JV results show accurate early diagnosis of bowel cancer |
|
| October 9, 2006 |
Peptech Update Issue #5 |
|
| September 27, 2006 |
Peptech surpasses milestone in progress to market launch |
|
| September 25, 2006 |
Suprelorin12® Registered in Australia |
|
| September 19, 2006 |
EvoGenix announced that it has successfully completed testing of its first product, EGX-010 for treatment of osteoporosis, in animal models for osteoporosis and bone cancer |
|
| September 5, 2006 |
Peptech corporate presentation |
|
| August 30, 2006 |
Peptech Boardroom radio interview transcript |
|
| August 30, 2006 |
Peptech Boardroom radio interview |
|
| August 10, 2006 |
Step forward for accurate diagnosis of prostate cancer |
|
| July 26, 2006 |
AusBiotech presentation - July 2006 |
|
| July 13, 2006 |
Domantis wins at prestigious UK Biotech awards |
|
| July 5, 2006 |
EvoGenix announced that it had been offered a Commercial Ready grant of $1.66 million over 2 years to advance work with its anti-cancer antibody DMF10. |
|
| June 28, 2006 |
Domantis appointment of new CFO |
|
| June 27, 2006 |
2006 Half Year Report |
|
| June 8, 2006 |
CEO and Board exhibit confidence - increase shareholdings |
|
| June 1, 2006 |
EvoGenix and CSL Limited announced agreement on a Technology Collaboration. EvoGenix will utilise its technology capabilities to develop improved antibodies for the CSL pipeline. |
|
| May 18, 2006 |
Peptech acquires Promics |
|
| April 10, 2006 |
EvoGenix announced in-licensing of a high-potential anti-cancer antibody from the University of Massachusetts in the USA |
|
| March 27, 2006 |
Peptech Update Issue #4 |
|
| February 15, 2006 |
Peptech paves way for aggressive growth in product pipeline |
|
| February 15, 2006 |
Peptech Limited AGM – February 2006 |
|
| February 6, 2006 |
Significant differentiation factor for drug candidate |
|
| January 25, 2006 |
Presentation to fund managers and institutions |
|
| January 24, 2006 |
Business development at forefront of new Peptech strategy |
|
| January 23, 2006 |
Peptech commits to using financial firepower for growth |
|
| January 16, 2006 |
EvoGenix CEO, Dr Merilyn Sleigh, presented results on successful scientific progress of the company's bone loss product at a major US conference |
|
| |
|
|
|
